Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06177015 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Name: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC — clinical trial record (NCT06177015)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2023-12-11

View on ClinicalTrials.gov ↗

Record status

This record was last updated December 26, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2023-12-22

Study Status v1

Re-verified, no change to tracked fields

2023-12-11

Original filing

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.

Trial Details

NCT Number	NCT06177015
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy
Enrollment	200 participants
Start Date	2023-12-11
Primary Completion	2025-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-12-26